

Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcar20>

Recognition Properties of Processing α -Glucosidase I and α -Glucosidase II

Wataru Hakamata^{a c}, Makoto Muroi^a, Toshiyuki Nishio^b, Tadatake Oku^b & Akira Takatsuki^a

^a Animal and Cellular Systems Laboratory, The Institute of Physical and Chemical Research (RIKEN), Saitama, Japan

^b Department of Biological Chemistry, College of Bioresource Sciences, Nihon University, Kanagawa, Japan

^c Division of Organic Chemistry, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan

Published online: 18 Aug 2006.

To cite this article: Wataru Hakamata, Makoto Muroi, Toshiyuki Nishio, Tadatake Oku & Akira Takatsuki (2004) Recognition Properties of Processing α -Glucosidase I and α -Glucosidase II, Journal of Carbohydrate Chemistry, 23:1, 27-39, DOI: [10.1081/CAR-120030022](https://doi.org/10.1081/CAR-120030022)

To link to this article: <http://dx.doi.org/10.1081/CAR-120030022>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Recognition Properties of Processing α -Glucosidase I and α -Glucosidase II

Wataru Hakamata,^{1,*} Makoto Muroi,¹ Toshiyuki Nishio,²
Tadatake Oku,² and Akira Takatsuki¹

¹Animal and Cellular Systems Laboratory, The Institute of Physical and
Chemical Research (RIKEN), Saitama, Japan

²Department of Biological Chemistry, College of Bioresource Sciences,
Nihon University, Kanagawa, Japan

ABSTRACT

All four possible monodeoxy derivatives of *p*-nitrophenyl α -D-glucopyranoside (PNP Glc) and 1-amino-2,6-anhydro-1-deoxy-D-*glycero*-D-*ido*-heptitol derivatives were prepared and used as substrates and inhibitors of rat liver processing α -glucosidases. α -Glucosidase II hydrolyzed the 2-deoxy derivative of PNP Glc (**1**); the hydrolysis of **1** was more rapid than that of PNP Glc. These results indicate that the presence of a C-2 hydroxyl group is not essential for the action of α -glucosidase II. In contrast, PNP Glc and all of the deoxy derivatives of PNP Glc **1–4** inhibited α -glucosidase I. These results indicate that α -glucosidase I does not necessarily need all of the hydroxyl groups of the glycon moiety for binding to the enzyme. 2,6-Anhydro-1-benzamide-D-*glycero*-D-*ido*-heptitol (**11**), with a terminal phenyl group, inhibited α -glucosidase I and α -glucosidase II. Both α -glucosidase I and II showed the same aglycon specificities. When probes **5–12** were assayed for their ability to inhibit processing by α -glucosidases at the cellular level, no effects on glycoprotein processing were observed.

Key Words: Processing glucosidase; Inhibitor; Substrate specificity; Deoxy glucoside.

*Correspondence: Wataru Hakamata, Division of Organic Chemistry, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan; Fax: 81-3-3707-6950; E-mail: hakamata@nihs.go.jp.

INTRODUCTION

Endoplasmic reticulum processing α -glucosidases are key enzymes in the biosynthesis of asparagine-linked oligosaccharides that catalyze the first processing event after the transfer of $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2$ to proteins. These enzymes are a target for inhibition by anti-viral agents that interfere with the formation of essential glycoproteins required in viral assembly, secretion, and infectivity.^[1–3] Substrate specificities are used to categorize enzymes and are important in designing structure-based inhibitors. We previously elucidated the glycon specificities of α -glucosidases (EC 3.2.1.20),^[4–6] α -galactosidases (EC 3.2.1.22),^[5,7] and α -mannosidases (EC 3.2.1.24)^[5,8] against all possible monodeoxy and monomethyl derivatives of the corresponding *p*-nitrophenyl α -D-glycopyranosides, and confirmed that some of them were good substrates for the enzymes. Next, we planned to investigate the glycon and aglycon specificities of the processing α -glucosidases I (EC 3.2.1.106), and α -glucosidases II (EC 3.2.1.84), in rat liver microsomes using synthetic probes **1–12** (Fig. 1). Four probes **1–4** were synthesized previously.^[4,7,8] Thus, these studies required the efficient synthesis of probes **5–12**.

These latter eight probes included 1-amino-2,6-anhydro-1-deoxy-D-*glycero*-D-*ido*-heptitol, which might mimic to a great extent the topography of α -D-glucopyranoside and modified aglycon of α -glucopyranoside.

In this report, we first describe the synthesis of probes **5–12** with modified aglycons. These compounds were evaluated with regard to their ability to inhibit processing α -glucosidase I and α -glucosidase II. All of the monodeoxy analogs of *p*-nitrophenyl α -D-glucopyranoside (PNP Glc) **1–4**, available from previous studies, were evaluated as substrates and inhibitors of both enzymes. Finally, probes **5–12** were also tested in a cell culture system. We divided the recognition properties of α -glucosidase I and α -glucosidase II into glycon-specific and aglycon-specific and discuss our findings.




Figure 1. Chemical structure of probes **1–12**.



RESULTS AND DISCUSSION


Synthesis of Heptitol Derivatives

The synthesis of the 1-amino-2,6-anhydro-1-deoxy-D-*glycero*-D-*ido*-heptitol derivatives (**5–12**) that were used in the present study is presented in Sch. 1. 2,3,4,6-Tetra-*O*-benzyl- α -D-glucopyranosyl cyanide (**13**)^[9] was used as a starting material for the synthesis of **5–12**. Compound **14**^[9] was coupled with acetoxyacetic acid, 3-hydroxypropionic acid, 4-hydroxybutyric acid, glutaric acid monomethyl ester, and adipic acid monomethyl ester to give **15**, **17–19**, and **21**, respectively.^[10] Compound **15** was treated with a base to afford **16**. Compounds **19** and **21** were treated with lithium aluminum hydride (LAH) in tetrahydrofuran (THF) to give **20** and **22**, respectively. Compound **14** was acylated with acetic anhydride, benzoyl chloride, and pivaloyl chloride in pyridine to give **23–25** in good yield, respectively. Treatment of the resulting amides (**16–18**, **20**, and **22–25**) with palladium hydroxide on carbon gave probes **5–12** in good yields. To the best of our knowledge, there have been no previous reports on the synthesis of probes **5–12**.

Specificities of Processing α -Glucosidases

D. M. Burns et al. have been reported that rat liver α -glucosidase II showed hydrolytic activity against PNP Glc.^[11] We investigated the specific activity of rat liver microsome α -glucosidase II in the hydrolysis^[11–14] of PNP Glc and its deoxy derivatives **1–4**. Clearly, of the four deoxy derivatives of PNP Glc, α -glucosidase II hydrolyzed only the 2-deoxy glucopyranoside (**1**); its activity with **1** appeared to be substantially higher than that with PNP Glc. Kinetic studies of the hydrolysis of PNP Glc and **1** were also carried out (Table 1). The V_{\max}/K_m value of α -glucosidase II for **1** was 3.7-fold greater than for PNP Glc, which indicated that probe **1** was a good substrate for the enzyme. These results also indicated that the C-2 hydroxyl group of the α -glucopyranoside residue is not indispensable for recognition between the substrate and α -glucosidase II.

In assays of the inhibitory effects of PNP Glc and probes **1–12** against processing α -glucosidase I and α -glucosidase II in rat liver microsomes, we used [³H]glucose-labeled



Scheme 1. Synthesis of probes **5–12**.



Table 1. Hydrolytic activity of processing α -glucosidase II.

Substrate	Relative rate of hydrolysis (%)	k_m (mM)	V_{max} (μ mol/min/unit)	V_{max}/k_m
PNP α -D-glucopyranoside	100	0.92	1.12	1.23
PNP 2-deoxy- α -D-glucopyranoside (1)	189	0.76	3.44	4.53
PNP 3-deoxy- α -D-glucopyranoside (2)	<1	—	—	—
PNP 4-deoxy- α -D-glucopyranoside (3)	<1	—	—	—
PNP 6-deoxy- α -D-glucopyranoside (4)	<1	—	—	—

Note: Relative rate of hydrolysis was expressed by comparison with the amount of *p*-nitrophenol that was released from PNP Glc by α -glucosidase II, which was taken as 100%.

vesicular stomatitis virus glycoprotein (VSV G)^[11–16] and PNP Glc as substrates, and the results are summarized in Table 2. PNP Glc and probes **1–4** inhibited α -glucosidase I. At 5 mM, PNP Glc and probes **1–4** inhibited α -glucosidase I by 56.2%, 71.7%, 18.5%, 22.2%, and 32.3%, respectively. On the other hand, PNP Glc and probes **1–4** at 5 mM did not inhibit α -glucosidase II. It has been reported that both PNP Glc and β -D-glucopyranoside inhibit purified mammary-gland α -glucosidase I, with 19% and *p*-nitrophenyl 14% inhibition at 0.5 μ M.^[17] These findings indicate that the C-2, C-3, C-4, and C-6 hydroxyl groups of the α -D-glucopyranoside residue are important for recognition of the substrate by α -glucosidase I. However, the C-2 hydroxyl group of the α -D-glucopyranoside residue is not critical for substrate recognition. The failure of the 3-, 4- and 6-deoxy derivatives

Table 2. Inhibitory activity against processing α -glucosidases.

Inhibition (%)	Enzyme	
	Glucosidase I	Glucosidase II
PNP Glc	56.2	HD
1	71.7	HD
2	18.5	<1.0
3	22.2	<1.0
4	32.3	<1.0
5	<1.0	<1.0
6	<1.0	<1.0
7	<1.0	<1.0
8	<1.0	<1.0
9	<1.0	<1.0
10	<1.0	<1.0
11	18.2	5.9
12	<1.0	<1.0

Note: Probe concentrations: Probes **1–4**: 5 mM; probes **5–12**: 2 mM. Substrate of glucosidase I: [³H]Glucose labeled VSV G. Substrate of glucosidase II: PNP Glc. HD: Hydrolyzing activity was observed.



(**2**, **3**, and **4**) to inhibit α -glucosidase II suggests that the C-3, C-4, and C-6 hydroxyl groups of α -D-glucopyranoside are important for substrate recognition by α -glucosidase II. Compound **11**, with a terminal phenyl group, moderately inhibited both enzymes. At 2 mM compound **11** inhibited α -glucosidase I by 18% and α -glucosidase II by 6%. Both α -glucosidase I and II showed the same aglycon specificities. Probes **5**–**12** were assayed with regard to their ability to inhibit glycoprotein processing at the cellular level. The VSV G was prepared from VSV-infected and probe-treated baby hamster kidney (BHK) cells. Analyses of the *N*-glycan structure of obtained VSV G using endo H, which is known to have hydrolytic activity against high-mannose type *N*-glycan, failed to confirm that these compounds inhibited processing α -glucosidases (data not shown).

Asano et al. and Muroi et al. reported that fagomine (a 2-deoxy derivative of 1-deoxynojirimycin) and 1-azafagomine (in which the C-1 methylene group of fagomine is replaced by an $-\text{NH}-$ group) inhibited processing α -glucosidases in rat liver microsomes.^[14,16] Based on these inhibitory activities and our data, fagomine and 1-azafagomine are considered to inhibit α -glucosidase II rather than α -glucosidase I.

We previously reported that the glycosyl hydrolase family 31 α -glucosidases from rice, sugar beet, flint corn, and *Aspergillus niger* had 2-deoxyglucosidase activity; its activity against **1** appeared to be substantially higher than that against PNP Glc.^[4,6] Therefore, rat liver microsome α -glucosidase II may have properties similar to those found in glycosyl hydrolase family 31.

EXPERIMENTAL

General Methods

Melting points were determined with a BÜCHI 510 capillary apparatus and are uncorrected. Optical rotations were measured with JASCO DIP-370 digital polarimeter at 25°C. The NMR spectra were recorded with a JEOL α -400 spectrometer (400 MHz for ^1H and 100 MHz for ^{13}C). Chemical shifts were expressed in ppm downfield shift from Me_4Si . Where appropriate, signal assignments were deduced by COSY and HMQC NMR experiments. Low- and high-resolution mass spectra were obtained with a JEOL JMS AX505WA instrument under positive ion FAB conditions. Column chromatography was performed on silica gel 60 (0.063–0.200 mm, Merck, Tokyo, Japan). The progress of all reactions was monitored by thin-layer chromatography on silica gel 60 F₂₅₄ (0.25 mm, Merck, Tokyo, Japan).

Method A

To the solution of compound **13**^[9] (1.6 mmol), in THF (30 mL), a suspension of LAH (3 mmol) in THF (5 mL) was slowly added. The mixture was stirred at room temperature for 1 hr and then quenched with ethyl acetate (AcOEt). The resulting mixture was diluted with satd Na_2SO_4 aq and extracted with diethyl ether (Et_2O). Evaporation of the Et_2O phase gave 1-amino-2,6-anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-D-*glycero*-D-*ido*-heptitol (**14**) (1.51 g, 94.4%) as unstable syrup.



Method B

To the solution of compound **14** (0.63 mmol) in dichloromethane (CH_2Cl_2 , 5 mL) and the mixture was added triethylamine (NEt_3 , 1.9 mmol), carboxylic acid (0.94 mmol) in CH_2Cl_2 (1 mL), and diphenylphosphoryl azide (0.94 mmol) in CH_2Cl_2 (1 mL). After stirring the mixture at 0°C for 8 hr. The resulting mixture was diluted with 1 M HCl_{aq} and extracted with Et_2O (2×80 mL). The organic extract was washed with satd NaHCO_3 _{aq}, and brine, and then concentrated after drying over Na_2SO_4 .

Method C

To the solution of compound **14** (1.38 mmol) in *N,N*-dimethylformamide (DMF, 15 mL) and the mixture was added NEt_3 (3.77 mmol), carboxylic acid (1.88 mmol) in DMF (2 mL) and diethylphosphoryl cyanide (1.88 mmol) in DMF (2 mL) was added.^[10] After stirring the mixture at 0°C for 18 hr. The resulting mixture was diluted with 1 M HCl_{aq} and extracted with Et_2O (3×50 mL). The organic extract was washed with satd NaHCO_3 _{aq}, and brine, and then concentrated after drying over Na_2SO_4 .

Method D

To the solution of methylester derivative (0.07 mmol), in THF (10 mL), a suspension of LAH (0.14 mmol) in THF (2 mL) was slowly added. The mixture was stirred at room temperature for 2 hr and then quenched with AcOEt. The resulting mixture was diluted with satd Na_2SO_4 _{aq} and extracted with Et_2O . The organic extract was washed with satd NaHCO_3 _{aq}, and brine, and then concentrated after drying over Na_2SO_4 .

Method E

To the solution of compound **14** (1.0 mmol), in pyridine (20 mL) at room temperature was added acyl halide (4.0 mmol). The mixture was stirred for overnight and poured into water. The product was extracted with AcOEt (3×50 mL) and washed with water, 1 M HCl_{aq}, satd NaHCO_3 _{aq}, and brine, and then dried over Na_2SO_4 . Removal of solvent afforded the corresponding amide.

Method F

A mixture of benzyloxy derivative (0.3 mmol) in ethanol (EtOH , 10 mL) and 1 M HCl_{aq} (50 μL) was hydrogenated under H_2 with 20% palladium hydroxide on carbon (20 mg). After stirring the mixture for 1 hr, the palladium charcoal was removed by filtration through Celite and the solvent was concentrated.



Preparation of Probes

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-1-[(1-oxoethyl-2-acetoxy)amino]-D-*glycero*-D-*ido*-heptitol (**15**)

According to methods A and B, compound **15** was prepared from **13** (1.14 g, 2.08 mmol). The product was purified by column chromatography on silica gel (1:1 hexane–AcOEt) to afford 0.44 g (32.6%) of **15**, which was recrystallized from hexane–AcOEt: $[\alpha]_D + 27.8^\circ$ (*c* 3.6, CHCl₃); mp 86–87°C; ¹H NMR (CDCl₃) δ 2.02 (s, 3H, –OCOCH₃), 3.42–3.81 (m, 8H, H-1, H-3, H-4, H-5, H-6, and H-7), 4.09 (m, 1H, H-2), 4.46–4.92 (4 AB system, 8H, –CH₂-Ph), 4.51 (s, 2H, –COCH₂O–), 6.37 (t, 1H, NH), 7.13–7.36 (m, 20H, aromatic H); MS: 654 (MH⁺).

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-1-[(1-oxoethyl-2-hydroxy)amino]-D-*glycero*-D-*ido*-heptitol (**16**)

A stirred solution of methanol (MeOH) : NEt₃ : H₂O (5 : 1 : 1, 14 mL) was added acetyl derivative **15** (0.18 g, 0.28 mmol). After the mixture was stirred for 3 hr at room temperature, solvent was evaporated. The product was purified by column chromatography on silica gel (AcOEt) to afford 0.16 g (96.7%) of **16**, which was recrystallized from hexane–AcOEt: $[\alpha]_D + 56.5^\circ$ (*c* 2.3, CHCl₃); mp 144–145°C; ¹H NMR (CDCl₃) δ 3.47–3.81 (m, 8H, H-1, H-3, H-4, H-5, H-6, and H-7), 3.96 (s, 2H, –CH₂OH), 4.10 (m, 1H, H-2), 4.44–4.90 (4 AB system, 8H, –CH₂-Ph), 6.62 (t, 1H, *J*_{NH, 1} 5.2 Hz, NH), 7.12–7.35 (m, 20H, aromatic H); MS: 612 (MH⁺).

2,6-Anhydro-1-deoxy-1-[(1-oxoethyl-2-hydroxy)amino]-D-*glycero*-D-*ido*-heptitol (**5**)

According to method F, compound **5** was prepared from **16** (80.0 mg, 0.13 mmol), the product was purified by column chromatography on silica gel (3 : 1 CH₂Cl₂–MeOH) to afford 32.4 mg (98.6%) of **5**: $[\alpha]_D + 20.0^\circ$ (*c* 0.6, MeOH); ¹H NMR (CD₃OD) δ 3.28 (dd, 1H, *J*_{4,5} = *J*_{5,6} 9.2 Hz, H-5), 3.54 (dd, 1H, *J*_{3,4} 8.8 Hz, H-4), 3.56–3.68 (m, 4H, H-1, H-6, and H-7a), 3.66 (dd, 1H, *J*_{2,3} 5.6 Hz, H-3), 3.78 (dd, 1H, *J*_{6,7b} 2.4 Hz, *J*_{7a,7b} 11.6 Hz, H-7b), 3.99 (s, 2H, H-2'), 4.03 (ddd, 1H, *J*_{2,3} 4.0 Hz, H-2); ¹³C NMR (CD₃OD) δ 36.02 (C-1), 62.64 (C-2'), 62.87 (C-7), 71.87 (C-5), 72.38 (C-3), 75.16 (C-6), 75.31 (C-4), 75.82 (C-2), 175.30 (C-1'); HRMS: Anal. calcd for C₉H₁₈NO₇ + H⁺; 252.1083. Found; 252.1095.

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-1-[(1-oxopropyl-3-hydroxy)amino]-D-*glycero*-D-*ido*-heptitol (**17**)

According to methods A and C, compound **17** was prepared from **13** (0.61 g, 1.11 mmol). The product was purified by column chromatography on silica gel (AcOEt) to afford 0.23 g (37.3%) of **17**, which was recrystallized from hexane–AcOEt: $[\alpha]_D + 55.0^\circ$ (*c* 1.2, CHCl₃); mp 113–115°C; ¹H NMR (CDCl₃) δ 2.26 (td, 2H, *J*_{2',3'} 5.8 Hz, *J*_{3',OH} 1.6 Hz, H-3'), 3.42–3.81 (m, 10H, H-1, H-3, H-4, H-5, H-6, H-7, and H-2'), 4.08 (m, 1H, H-2), 4.45–4.91 (4 AB system, 8H, –CH₂-Ph), 6.09 (bs, 1H, NH), 7.14–7.35 (m, 20H, aromatic H); MS: 626 (MH⁺).



2,6-Anhydro-1-deoxy-1-[(1-oxopropyl-3-hydroxy)amino]-D-glycero-D-ido-heptitol (**6**)

According to method F, compound **6** was prepared from **17** (60.1 mg, 96 μ mol), the product was purified by column chromatography on silica gel (10:4:2:1 CH₂Cl₂–MeOH–EtOH–H₂O) to afford 20.1 mg (78.9%) of **6**: [α]_D + 66.7° (*c* 1.0, MeOH); ¹H NMR (CD₃OD) δ 2.43 (t, 2H, *J*_{2',3'} 6.4 Hz, H-3'), 3.23 (dd, 1H, *J*_{4,5} = *J*_{5,6} 9.0 Hz, H-5), 3.46–3.56 (m, 2H, H-1a and H-6), 3.52 (dd, 1H, *J*_{3,4} 8.8 Hz, H-4), 3.59–3.66 (m, 3H, H-1b, H-3, and H-7a), 3.79–3.82 (dd, 1H, H-7b), 3.80 (t, 2H, H-2'), 4.00 (ddd, 1H, *J*_{1,2} 4.2 Hz, *J*_{1,2} 10.2 Hz, *J*_{2,3} 6.0 Hz, H-2); ¹³C NMR (CD₃OD) δ 36.25 (C-1), 40.10 (C-3'), 59.43 (C-2'), 63.12 (C-7), 72.04 (C-5), 72.35 (C-3), 75.11 (C-6), 75.26 (C-4), 75.90 (C-2), 174.37 (C-1'); HRMS: Anal. calcd for C₁₀H₂₀NO₇ + H⁺; 266.1240. Found; 266.1236.

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-1-[(1-oxobutyl-4-hydroxy)amino]-D-glycero-D-ido-heptitol (**18**)

According to methods A and C, compound **18** was prepared from **13** (0.52 g, 0.95 mmol). The product was purified by column chromatography on silica gel (AcOEt) to afford 0.23 g (41.3%) of **18**, which was recrystallized from hexane–AcOEt: [α]_D + 62.0° (*c* 1.0, CHCl₃); mp 138–139°C; ¹H NMR (CDCl₃) δ 1.78 (tt, 2H, *J*_{2',3'} 12.4 Hz, *J*_{3',4'} 6.2 Hz, H-3'), 2.23 (td, 2H, *J*_{4',OH} 1.4 Hz, H-4'), 3.40–3.80 (m, 10H, H-1, H-3, H-4, H-5, H-6, H-7, and H-2'), 4.09 (m, 1H, H-2), 4.45–4.91 (4 AB system, 8H, –CH₂–Ph), 6.21 (m, 1H, NH), 7.13–7.36 (m, 20H, aromatic H); MS: 640 (MH⁺).

2,6-Anhydro-1-deoxy-1-[(1-oxobutyl-4-hydroxy)amino]-D-glycero-D-ido-heptitol (**7**)

According to method F, compound **7** was prepared from **18** (168 mg, 0.26 mmol), the product was purified by column chromatography on silica gel (10:4:2:1 CH₂Cl₂–MeOH–EtOH–H₂O) to afford 72.1 mg (98.5%) of **7**: [α]_D + 70.0° (*c* 0.8, MeOH); ¹H NMR (CD₃OD) δ 1.81 (tt, 2H, *J*_{2',3'} = *J*_{3',4'} 6.8 Hz, H-3'), 2.30 (t, 2H, H-3'), 3.24 (dd, 1H, *J*_{4,5} = *J*_{5,6} 8.8 Hz, H-5), 3.43–3.53 (m, 3H, H-1a, H-4, and H-6), 3.57 (t, 2H, H-2'), 3.59–3.66 (m, 3H, H-1b, H-3, and H-7a), 3.80 (dd, 1H, *J*_{6,7b} 2.4 Hz, *J*_{7a,7b} 11.6 Hz, H-7b), 3.98 (ddd, 1H, *J*_{1,2} 4.0 Hz, *J*_{1,2} 10.8 Hz, *J*_{2,3} 5.6 Hz, H-2); ¹³C NMR (CD₃OD) δ 29.80 (C-3'), 33.63 (C-4'), 36.22 (C-1), 62.26 (C-2'), 63.10 (C-7), 72.04 (C-5), 72.37 (C-3), 75.15 (C-6), 75.21 (C-4), 76.01 (C-2), 176.13 (C-1'); HRMS: Anal. calcd for C₁₁H₂₂NO₇ + H⁺; 280.1396. Found; 280.1393.

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-1-[(1-methoxycarbonyl)propylcarbonylamino]-D-glycero-D-ido-heptitol (**19**)

According to methods A and B, compound **19** was prepared from **13** (0.35 g, 0.63 mmol). The product was purified by column chromatography on silica gel (1:1 hexane–AcOEt) to afford 0.27 g (63.2%) of **19**, which was recrystallized from hexane–AcOEt: [α]_D + 38.7° (*c* 1.5, CHCl₃); mp 113–115°C; ¹H NMR (CDCl₃) δ 2.11 (tt, 2H, *J*_{2',3'} = *J*_{3',4'} 7.4 Hz, H-3'), 2.31 (t, 2H, H-2'), 3.44–3.78 (m, 10H, H-1, H-3, H-4, H-5, H-6,



H-7, and H-4'), 3.65 (s, 3H, -OMe) 4.06 (m, 1H, H-2), 4.46–4.91 (4 AB system, 8H, -CH₂-Ph), 5.79 (m, 1H, NH), 7.13–7.36 (m, 20H, aromatic H); MS: 682 (MH⁺).

2,6-Anhydro-3, 4, 5, 7-tetra-*O*-benzyl-1-deoxy-1-[(1-oxopentyl-5-hydroxy) amino]-D-*glycero*-D-*ido*-heptitol (**20**)

According to method D, compound **20** was prepared from **19** (0.55 g, 0.81 mmol), the product was purified by column chromatography on silica gel (1:6 hexane–AcOEt) to afford 0.38 g (72.5%) of **20**, which was recrystallized from hexane–AcOEt: [α]_D + 45.3° (*c* 1.5, CHCl₃); mp 130–131°C; ¹H NMR (CDCl₃) δ 1.53 (tt, 2H, $J_{3',4'} = J_{4',5'}$ 8.0 Hz, H-4'), 1.67 (tt, 2H, $J_{2',3'}$ 8.0 Hz, H-3'), 2.14 (t, 2H, H-5'), 3.41–3.80 (m, 10H, H-1, H-3, H-4, H-5, H-6, H-7, and H-2'), 4.09 (m, 1H, H-2), 4.45–4.91 (4 AB system, 8H, -CH₂-Ph), 6.04 (m, 1H, NH), 7.13–7.35 (m, 20H, aromatic H); MS: 654 (MH⁺).

2,6-Anhydro-1-deoxy-1-[(1-oxopentyl-5-hydroxy)amino]-D-*glycero*-D-*ido*-heptitol (**8**)

According to method F, compound **8** was prepared from **19** (269.8 mg, 0.41 mmol), the product was purified by column chromatography on silica gel (10:4:2:1 CH₂Cl₂–MeOH–EtOH–H₂O) to afford 92.6 mg (76.5%) of **8**: [α]_D + 36.4° (*c* 1.1, MeOH); ¹H NMR (CD₃OD) δ 1.55 (tt, 2H, H-3'), 1.67 (tt, 2H, H-4'), 2.24 (t, 2H, $J_{4',5'}$ 7.4 Hz, H-5'), 3.24 (dd, 1H, $J_{4,5} = J_{5,6}$ 9.2 Hz, H-5), 3.43–3.53 (m, 2H, H-1a and H-6), 3.56 (dd, 1H, $J_{3,4}$ 9.0 Hz, H-4), 3.56 (t, 2H, $J_{2',3'}$ 6.4 Hz, H-2'), 3.59–3.67 (m, 3H, H-1b, H-3, and H-7a), 3.80 (dd, 1H, $J_{6,7b}$ 2.2 Hz, $J_{7a,7b}$ 11.8 Hz, H-7b), 3.98 (ddd, 1H, $J_{1,2}$ 3.6 Hz, $J_{1,2}$ 10.8 Hz, $J_{2,3}$ 5.8 Hz, H-2); ¹³C NMR (CD₃OD) δ 23.41 (C-4'), 33.06 (C-3'), 36.17 (C-1), 36.76 (C-5'), 62.53 (C-2'), 63.09 (C-7), 72.02 (C-5), 72.37 (C-3), 75.15 (C-6), 75.20 (C-4), 76.07 (C-2), 176.32 (C-1'); HRMS: Anal. calcd for C₁₂H₂₄NO₇ + H⁺; 294.1553. Found; 294.1556.

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-1-[(1-methoxycarbonyl) butylcarbonylamino]-D-*glycero*-D-*ido*-heptitol (**21**)

According to methods A and B, compound **21** was prepared from **13** (0.45 g, 0.81 mmol). The product was purified by column chromatography on silica gel (1:1 hexane–AcOEt) to afford 0.12 g (21.3%) of **21**, which was recrystallized from hexane–AcOEt: [α]_D + 39.0° (*c* 2.0, CHCl₃); mp 104–105°C; ¹H NMR (CDCl₃) δ 1.60 (tt, 2H, $J_{2',3'} = J_{3',4'}$ 7.2 Hz, H-3'), 2.06 (tt, 2H, $J_{4',5'}$ 6.8 Hz, H-4'), 2.28 (t, 2H, H-2'), 3.43–3.79 (m, 10H, H-1, H-3, H-4, H-5, H-6, H-7, and H-5'), 3.65 (s, 3H, -OMe), 4.07 (m, 1H, H-2), 4.46–4.91 (4 AB system, 8H, -CH₂-Ph), 5.78 (m, 1H, NH), 7.13–7.32 (m, 20H, aromatic H); MS: 696 (MH⁺).

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-deoxy-1-[(1-oxohexyl-6-hydroxy)amino]-D-*glycero*-D-*ido*-heptitol (**22**)

According to method D, compound **22** was prepared from **21** (0.214 g, 0.31 mmol), the product was recrystallized from hexane–AcOE to afford 0.184 g (89.6%) of **22**: [α]_D + 50.1° (*c* 1.7, CHCl₃); mp 152–153°C; ¹H NMR (CDCl₃) δ 1.33 (tt, 2H, $J_{3',4'} = J_{4',5'}$ 7.6 Hz, H-4'), 1.52 (tt, 2H, $J_{5',6'}$ 7.4 Hz, H-5'), 1.60 (tt, 2H, $J_{2',3'}$ 7.6 Hz, H-3'),



2.09 (t, 2H, H-6'), 3.37–3.78 (m, 10H, H-1, H-3, H-4, H-5, H-6, H-7, and H-2'), 4.08 (m, 1H, H-2), 4.46–4.94 (4 AB system, 8H, $-\text{CH}_2\text{-Ph}$), 5.92 (m, 1H, NH), 7.14–7.34 (m, 20H, aromatic H); MS: 668 (MH^+).

2,6-Anhydro-1-deoxy-1-[(1-oxohexyl-6-hydroxy)amino]-D-glycero-D-ido-heptitol (**9**)

According to method F, compound **9** was prepared from **22** (132 mg, 0.20 mmol), the product was purified by column chromatography on silica gel (10:4:2:1 $\text{CH}_2\text{Cl}_2\text{-MeOH-EtOH-H}_2\text{O}$) to afford 60.4 mg (99.3%) of **9**: $[\alpha]_{\text{D}} + 88.6^\circ$ (c 0.7, MeOH); ^1H NMR (CD_3OD) δ 1.39 (tt, 2H, H-4'), 1.54 (tt, 2H, H-3'), 1.64 (tt, 2H, H-5'), 2.24 (t, 2H, $J_{5',6'}$ 7.6 Hz, H-6'), 3.25 (dd, 1H, $J_{4,5} = J_{5,6}$ 9.2 Hz, H-5), 3.43–3.53 (m, 3H, H-1a, H-4, and H-6), 3.55 (t, 2H, $J_{2',3'}$ 6.4 Hz, H-2'), 3.56–3.67 (m, 3H, H-1b, H-3, and H-7a), 3.78 (dd, 1H, $J_{6,7b}$ 2.0 Hz, $J_{7a,7b}$ 12.0 Hz, H-7b), 3.98 (ddd, 1H, $J_{1,2}$ 3.6 Hz, $J_{1,2}$ 11.0 Hz, $J_{2,3}$ 5.8 Hz, H-2); ^{13}C NMR (CD_3OD) δ 26.54 (C-4'), 26.84 (C-5'), 33.32 (C-3'), 36.17 (C-7), 37.04 (C-6'), 62.77 (C-2'), 63.07 (C-1), 72.02 (C-5), 72.34 (C-3), 75.13 (C-6), 75.18 (C-4), 76.03 (C-2), 176.41 (C-1'); HRMS: Anal. calcd for $\text{C}_{13}\text{H}_{26}\text{NO}_7 + \text{H}^+$; 308.1709. Found; 308.1702.

1-Acetamide-2,6-anhydro-D-glycero-D-ido-heptitol (**10**)

According to method F, compound **10** was prepared from **23** (0.16 mg, 0.27 mmol),^[9] the product was purified by column chromatography on silica gel (10:4:2:1 $\text{CH}_2\text{Cl}_2\text{-MeOH-EtOH-H}_2\text{O}$) to afford 63.2 mg (98.9%) of **6**: $[\alpha]_{\text{D}} + 26.0^\circ$ (c 1.0, MeOH); ^1H NMR (CD_3OD) δ 1.96 (s, 3H, COCH_3), 3.24 (dd, 1H, $J_{4,5} = J_{5,6}$ 9.0 Hz, H-5), 3.45 (dd, 1H, $J_{6,7a}$ 11.2 Hz, $J_{7a,7b}$ 14.4, H-7a), 3.51 (dd, 1H, $J_{3,4}$ 9.0 Hz, H-4), 3.54 (m, 1H, H-6), 3.59–3.64 (m, 3H, H-1 and H-7a), 3.65 (dd, 1H, $J_{2,3}$ 6.2 Hz, H-3), 3.80 (dd, 1H, $J_{7a,7b}$ 2.4 Hz, $J_{6,7b}$ 11.6 Hz, H-7b), 3.98 (ddd, 1H, $J_{1a,2}$ 3.6 Hz, H-2); ^{13}C NMR (CD_3OD) δ 22.56 (CH_3), 36.26 (C-1), 63.09 (C-7), 72.02 (C-5), 72.30 (C-3), 75.08 (C-4), 75.20 (C-6), 76.00 (C-2), 173.75 (C=O); HRMS: Anal. calcd for $\text{C}_9\text{H}_{18}\text{NO}_6 + \text{H}^+$; 236.1134. Found; 236.1135.

2,6-Anhydro-1-benzamide-3,4,5,7-tetra-O-benzyl-D-glycero-D-ido-heptitol (**24**)

According to methods A and E, compound **24** was prepared from **13** (0.54 g, 0.98 mmol), the product was purified by column chromatography on silica gel (AcOEt) to afford 0.38 mg (70.4%) of **24**, which was recrystallized from hexane– AcOEt : $[\alpha]_{\text{D}} + 68.3^\circ$ (c 1.2, CHCl_3); mp 141–143°C; ^1H NMR (CDCl_3) δ 3.51 (dd, 1H, $J_{4,5} = J_{5,6}$ 9.0 Hz, H-5), 3.59 (dd, 1H, $J_{6,7a}$ 5.4 Hz, $J_{7a,7b}$ 10.2 Hz, H-7a), 3.67 (dd, 1H, $J_{6,7b}$ 2.0 Hz, H-7b), 3.68–3.87 (m, 4H, H-1a, H-3, H-4, and H-6), 3.97 (ddd, 1H, $J_{1a,1b}$ 14.8 Hz, $J_{1b,2}$ 6.4 Hz, $J_{1b,\text{NH}}$ 5.0 Hz, H-1b), 4.21 (ddd, 1H, H-2), 4.47–4.92 (4 AB system, 8H, $-\text{CH}_2\text{-Ph}$), 6.55 (bs, 1H, NH), 7.14–7.71 (m, 24H, aromatic H); MS: 658 (MH^+).

2,6-Anhydro-1-benzamide-D-glycero-D-ido-heptitol (**11**)

According to method F, compound **11** was prepared from **24** (0.20 g, 0.30 mmol), the product was purified by column chromatography on silica gel (5:1 $\text{CH}_2\text{Cl}_2\text{-MeOH}$) to



Processing α -Glucosidase I and II

37

afford 77.6 mg (87.9%) of **11**: $[\alpha]_D + 107.5^\circ$ (*c* 0.8, MeOH); ^1H NMR (CD_3OD) δ 3.23 (dd, 1H, $J_{4,5} = J_{5,6}$ 9.4 Hz, H-5), 3.53 (dd, 1H, $J_{3,4}$ 9.0 Hz, H-4), 3.58–3.65 (m, 3H, H-3, H-6, and H-7a), 3.66 (dd, 1H, $J_{1a,1b} = J_{1a,2}$ 10.8 Hz, H-1a), 3.74–3.79 (m, 2H, H-1b and H-7b), 4.10 (ddd, 1H, $J_{1,2}$ 4.0 Hz, $J_{2,3}$ 6.5 Hz, H-2), 7.38–7.79 (m, 4H, aromatic H); ^{13}C NMR (CD_3OD) δ 36.88 (C-1), 63.04 (C-7), 72.06 (C-5), 72.42 (C-3), 75.25 (C-4 and C-6), 76.06 (C-2), 128.34, 129.52, 132.62, and 135.78 (aromatic C), 170.64 (C=O); HRMS: Anal. calcd for $\text{C}_{14}\text{H}_{20}\text{NO}_6 + \text{H}^+$; 298.1291. Found; 298.1287.

2,6-Anhydro-3,4,5,7-tetra-*O*-benzyl-1-trimethylacetamide-D-*glycero*-D-*ido*-heptitol (**25**)

According to methods A and E, compound **25** was prepared from **13** (0.61 g, 1.10 mmol), the product was purified by column chromatography on silica gel (AcOEt) to afford 0.65 g (72.3%) of **25**: $[\alpha]_D + 35.6^\circ$ (*c* 1.8, CHCl_3); ^1H NMR (CDCl_3) δ 1.12 (s, 9H, $\text{C}(\text{CH}_3)_3$), 3.42–3.83 (m, 8H, H-1, H-3, H-4, H-5, H-6 and H-7), 4.11 (ddd, 1H, $J_{1a,2} = J_{2,3}$ 4.8 Hz, $J_{1b,2}$ 9.6 Hz, H-2), 4.46–4.91 (4 AB system, 8H, $-\text{CH}_2-\text{Ph}$), 5.98 (bs, 1H, NH), 7.14–7.35 (m, 20H, aromatic H); MS: 638 (MH^+).

2,6-Anhydro-1-trimethylacetamide-D-*glycero*-D-*ido*-heptitol (**12**)

According to method F, compound **12** was prepared from **25** (0.17 g, 0.26 mmol), the product was purified by column chromatography on silica gel (4:1 CH_2Cl_2 –MeOH) to afford 64.8 mg (89.1%) of **12**: $[\alpha]_D + 105.0^\circ$ (*c* 0.8, MeOH); ^1H NMR (CD_3OD) δ 1.18 (s, 9H, $3 \times \text{CH}_3$), 3.25 (dd, 1H, $J_{4,5}$ 9.6 Hz, $J_{5,6}$ 8.8 Hz, H-5), 3.50–3.56 (m, 4H, H-4, H-6, and H-1), 3.63 (dd, 1H, $J_{2,3}$ 6.0 Hz, $J_{3,4}$ 9.6 Hz, H-3), 3.65 (dd, 1H, $J_{7a,7b}$ 2.0 Hz, $J_{6,7a}$ 6.0 Hz, H-7a), 3.77 (dd, $J_{6,7b}$ 11.8 Hz, H-7b), 4.00 (ddd, 1H, H-2); ^{13}C NMR (CD_3OD) δ 27.82 ($3 \times \text{CH}_3$), 36.69 (C-1), 39.74 ($\text{C}(\text{CH}_3)_3$), 62.95 (C-7), 72.00 (C-5), 72.55 (C-3), 75.28 (C-4 and C-6), 75.71 (C-2), 181.59 (C=O); HRMS: Anal. calcd for $\text{C}_{12}\text{H}_{24}\text{NO}_6 + \text{H}^+$; 278.1604. Found; 278.1601.

Enzymatic Assays

p-Nitrophenyl α -D-glucopyranoside was purchased from Sigma–Aldrich Inc. [^3H]Glucose labeled VSV G was prepared as previously reported methods.^[15,18,19] Rat liver microsomes were prepared following the previously reported methods, and membranes were collected by centrifugation at 12,000g for 1 hr and resuspended in 100 mM potassium phosphate buffer (pH 6.8) containing 10 mM glycerol, 2 mM MgCl_2 , 0.5 μM DTT.^[15] Activities of processing α -glucosidase I and α -glucosidase II were assayed using rat liver microsomes as an enzyme source. In assays of the inhibitory effects of PNP Glc and probes **1–12** against processing α -glucosidase I, we used [^3H]glucose labeled VSV G as substrate. The hydrolytic activities of the enzyme was assayed by measuring the release of [^3H]glucose under 100 mM potassium phosphate buffer (pH 6.8) containing 20 mM EDTA, 0.02% NaN_3 , 0.05% Triton X-100, and protease inhibitor cocktails at 37°C. The processing α -glucosidase II assays were performed by using PNP Glc as substrate and were assayed the previously reported methods,^[11–14] the assay condition was 100 mM potassium phosphate buffer containing 0.05% Triton X-100 (pH 6.8) at 37°C. One unit of enzyme activity was defined as



the amount of enzyme required to liberate 1 μmol of *p*-nitrophenol/min at each assay condition. Kinetic study on the hydrolysis of PNP Glc and **1** by α -glucosidase II was performed at each concentration, and values of K_m (mM) and V_{max} ($\mu\text{mol}/\text{min}/\text{unit}$) were calculated from reciprocal plots of their reaction curves.

Inhibition Assays at Cellular Level

Confluent monolayer of BHK cells are infected with the VSV, and nectrisine (a final concentration 10 $\mu\text{g}/\text{mL}$, Nectrisine was kindly supplied from Fujisawa Pharmaceutical Co., Tokyo, Japan), probes **5–10** and **12** (final concentrations 100 $\mu\text{g}/\text{mL}$), and probe **11** (a final concentration 500 $\mu\text{g}/\text{mL}$) are added to infected cultures as described.^[18–20] The obtained VSV G proteins were digested with endo H by reported method.^[18] The treated VSV G proteins were subjected to SDS-polyacrylamide gel electrophoresis using 10% acryl amide gel, followed by electrophoretic transfer onto nitrocellulose membrane. The protein replica was incubated with rabbit polyclonal antibodies raised against VSV G.^[18] Antigen–antibody complexes were detected with a goat anti-rabbit IgG antibody–alkaline phosphatase conjugate by staining with 5-bromo-4-chloro-3-indolyl phosphate.

ACKNOWLEDGMENTS

This work was preformed at Special Postdoctoral Researchers Program (RIKEN).

REFERENCES

1. Mehta, A.; Zitzmann, N.; Rudd, P.M.; Block, T.M.; Dwek, R.A. α -Glucosidase inhibitors as potential broad based anti-viral agents. *FEBS Lett.* **1998**, *430*, 17–22.
2. Herscovics, A. Processing glycosidases of *Saccharomyces cerevisiae*. *Biochim. Biophys. Acta.* **1999**, *1426*, 275–285.
3. De Praeter, C.M.; Gerwig, G.J.; Bause, E.; Nuytinck, L.K.; Vliegenthart, J.F.G.; Breuer, W.; Kamerling, J.P.; Espeel, M.F.; Martin, J.J.R.; De Paepe, A.M.; Chan, N.W.C.; Dacremont, G.A.; Van Coster, R.N. A novel disorder caused by defective biosynthesis of *N*-linked oligosaccharides due to glucosidase I deficiency. *Am. J. Hum. Genet.* **2000**, *66*, 1744–1756.
4. Hakamata, W.; Nishio, T.; Oku, T. Synthesis of *p*-nitrophenyl 3- and 6-deoxy- α -D-glucopyranosides and their specificity to rice α -glucosidase. *J. Appl. Glycosci.* **1999**, *46*, 459–463.
5. Hakamata, W.; Nishio, T.; Sato, R.; Mochizuki, T.; Tsuchiya, K.; Yasuda, M.; Oku, T. Synthesis of monomethyl derivatives of *p*-nitrophenyl α -D-gluco-, galacto-, and mannopyranosides and their hydrolytic properties against α -glycosidase. *J. Carbohydr. Chem.* **2000**, *19*, 359–377.
6. Nishio, T.; Hakamata, W.; Kimura, A.; Chiba, S.; Takatsuki, A.; Kawachi, R.; Oku, T. Glycon specificity profiling of α -glucosidases using monodeoxy and mono-*O*-methyl derivatives of *p*-nitrophenyl α -D-glucopyranoside. *Carbohydr. Res.* **2002**, *337*, 629–634.

7. Hakamata, W.; Nishio, T.; Oku, T. Hydrolytic activity of α -galactosidases against deoxy derivatives of *p*-nitrophenyl α -D-galactopyranoside. *Carbohydr. Res.* **2000**, *324*, 107–115.
8. Nishio, T.; Miyake, Y.; Tsujii, H.; Hakamata, W.; Kadokura, K.; Oku, T. Hydrolytic activity of α -mannosidase against deoxy derivatives of *p*-nitrophenyl α -D-mannopyranoside. *Biosci. Biotech. Biochem.* **1996**, *60*, 2038–2042.
9. López, M.-T.G.; De las Heras, F.G.; Félix, A.S. Cyanosugars IV. Synthesis of α -D-glucopyranosyl and α -D-galactopyranosyl cyanides and related 1,2-*cis* C-glycoside. *J. Carbohydr. Chem.* **1987**, *6*, 273–279.
10. Suhara, Y.; Ichikawa, M.; Hildreth, J.E.K.; Ichikawa, Y. Synthesis of sulfated β -1,6-linked oligosaccharide mimetics: a novel potent inhibitor of HIV replication. *Tetrahedron Lett.* **1994**, *37*, 2549–2552.
11. Burns, D.M.; Touster, O. Purification and characterization of glucosidase II, an endoplasmic reticulum hydrolase involved in glycoprotein biosynthesis. *J. Biol. Chem.* **1982**, *257*, 9991–10000.
12. Hino, Y.; Rothman, J.E. Glucosidase II, a glycoprotein of the endoplasmic reticulum membrane. Proteolytic cleavage into enzymatically active fragments. *Biochemistry* **1985**, *24*, 800–805.
13. Bause, E.; Schweden, J.; Gross, A.; Orthen, B. Purification and characterization of trimming glucosidase I from pig liver. *Eur. J. Biochem.* **1989**, *183*, 661–669.
14. Asano, N.; Oseki, K.; Kizu, H.; Matsui, K. Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. *J. Med. Chem.* **1994**, *59*, 3701–3706.
15. Tsujii, E.; Muroi, M.; Shiragami, N.; Takatsuki, A. Nectrisine is a potent inhibitor of α -glucosidases, demonstrating activities similarly at enzyme and cellular levels. *Biophys. Biophys. Res. Commun.* **1996**, *220*, 459–466.
16. Muroi, M.; Ando, O.; Bols, M.; Takatsuki, A. Processing glucosidase inhibition by I-azafagomine. *Biosci. Biotech. Biochem.* **2000**, *164*, 1103–1105.
17. Shailubhai, K.; Pratta, M.A.; Vijay, I.K. Purification and characterization of glucosidase I involved in *N*-linked glycoprotein processing in bovine mammary gland. *Biochem. J.* **1987**, *247*, 555–562.
18. Muroi, M.; Takasu, A.; Yamasaki, M.; Takatsuki, A. Folimycin (Concanamycin A), an inhibitor of V-type H^+ -ATPase, blocks cell-surface expression of virus-envelope glycoprotein. *Biophys. Biophys. Res. Commun.* **1993**, *193*, 999–1005.
19. Muroi, M.; Shiragami, N.; Nagano, K.; Yamasaki, M.; Takatsuki, A. Folimycin (Concanamycin A), a specific inhibitor of V-ATPase, blocks intercellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the golgi apparatus. *Cell Struct. Funct.* **1993**, *18*, 139–149.
20. Kaushal, G.P.; Elbein, A.D. Glycosidase inhibitor in study of glycoconjugates. *Methods Enzymol.* **1994**, *230*, 316–329.

Received June 19, 2003

Revised July 4, 2003

Accepted August 7, 2003



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Order Reprints" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

Request Permission/Order Reprints

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081CAR120030022>